Asahi Kasei License Rights To Osteoporosis Drug From Novartis
This article was originally published in PharmAsia News
Asahi Kasei Pharma signed a license agreement with Novartis and obtained the exclusive rights to develop and market zoledronic for osteoporosis in Japan
You may also be interested in...
Abbott reported strong sales for diagnostics and devices in the third quarter and raised its full-year EPS guidance to $3.55 per share.
Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.
A randomized trial demonstrated the superiority of Medtronic’s DTM spinal cord stimulation waveform over conventional spinal cord stimulation for treating back pain.